Jerry R Mendell
Overview
Explore the profile of Jerry R Mendell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
193
Citations
10600
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lowes L, Reash N, Iammarino M, Connolly A, Pietruszewski L, Smith M, et al.
J Neuromuscul Dis
. 2025 Feb;
11(6):1260-1267.
PMID: 39973462
Background: Duchenne muscular dystrophy (DMD), an X-linked progressive neurodegenerative disorder, is being added to required universal screening programs for newborns in the United States. It is estimated that this will...
2.
Mendell J, Muntoni F, McDonald C, Mercuri E, Ciafaloni E, Komaki H, et al.
Nat Med
. 2024 Oct;
31(1):332-341.
PMID: 39385046
Duchenne muscular dystrophy (DMD) is a rare, X-linked neuromuscular disease caused by pathogenic variants in the DMD gene that result in the absence of functional dystrophin, beginning at birth and...
3.
Lowes L, Alfano L, Iammarino M, Reash N, Giblin K, Hu L, et al.
PLoS One
. 2024 May;
19(5):e0300700.
PMID: 38753764
Conducting functional assessments remotely can help alleviate the burden of in-person assessment on patients with Duchenne muscular dystrophy and their caregivers. The objective of this study was to evaluate whether...
4.
Zaidman C, Goedeker N, Aqul A, Butterfield R, Connolly A, Crystal R, et al.
J Neuromuscul Dis
. 2024 Apr;
11(3):687-699.
PMID: 38607761
Background: Duchenne muscular dystrophy (DMD) is a rare, degenerative, recessive X-linked neuromuscular disease. Mutations in the gene encoding dystrophin lead to the absence of functional dystrophin protein. Individuals living with...
5.
Potter R, Peterson E, Griffin D, Cooper Olson G, Lewis S, Cochran K, et al.
Mol Ther Methods Clin Dev
. 2024 Feb;
32(1):101195.
PMID: 38327805
Patients with pre-existing immunity to adeno-associated virus (AAV) are currently unable to receive systemic gene transfer therapies. In this nonhuman primate study, we investigated the impact of immunosuppression strategies on...
6.
Mendell J, Proud C, Zaidman C, Mason S, Darton E, Wang S, et al.
Pediatr Neurol
. 2024 Feb;
153:11-18.
PMID: 38306745
Background: Delandistrogene moxeparvovec is a gene transfer therapy approved in the United States, United Arab Emirates, and Qatar for the treatment of ambulatory patients aged four through five years with...
7.
Mendell J, Pozsgai E, Lewis S, Griffin D, Lowes L, Alfano L, et al.
Nat Med
. 2024 Jan;
30(1):199-206.
PMID: 38177855
Limb-girdle muscular dystrophy 2E/R4 is caused by mutations in the β-sarcoglycan (SGCB) gene, leading to SGCB deficiency and consequent muscle loss. We developed a gene therapy approach based on functional...
8.
Waldrop M, Chagat S, Storey M, Meyer A, Iammarino M, Reash N, et al.
Neuromuscul Disord
. 2023 Dec;
34:41-48.
PMID: 38142474
5q spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disease caused by absence of the SMN1 gene with three FDA approved genetic therapies which significantly improve outcomes. The AAV9...
9.
Day J, Mendell J, Burghes A, van Olden R, Adhikary R, Dilly K
Mol Ther Methods Clin Dev
. 2023 Oct;
31:101117.
PMID: 37822718
Onasemnogene abeparvovec is a recombinant adeno-associated virus serotype 9 (AAV9) vector-based gene therapy for spinal muscular atrophy (SMA). Patients with elevated titers of anti-AAV9 antibodies (AAV9-Ab) should not receive onasemnogene...
10.
DAmbrosio E, Mendell J
Neurotherapeutics
. 2023 Sep;
20(6):1669-1681.
PMID: 37673849
Duchenne muscular dystrophy (DMD) is the most common childhood form of muscular dystrophy. It is caused by mutations in the DMD gene, leading to reduced or absent expression of the...